SLXN - Rasio rega marang prakiraan pendapatan Silexion Therapeutics Corp.

Silexion Therapeutics (SLXN) - logo korporat

Silexion Therapeutics Corp (SLXN) is implementing energy-saving technologies and emission filtration within its laboratories. The expected P/S metric confirms the current trend, with the latest reading standing at 0.00. Outlooks are based on the expansion of RNA therapy against pancreatic cancer; however, high capital expenditure requirements in the absence of commercial products create a risk of depleting cash reserves.

Silexion - Prakiraan rega marang pendapatan SLXN (periode 17.08.2024 - 17.08.2024)

Rincian metrik komprehensif lan analitis Silexion (SLXN)

- rega pasar lan target rega analis:
Analisis umum perusahaan:Silexion Therapeutics SLXN
Produk sing diprodhuksi Silexion Therapeutics Corp.

The forward P/S ratio measures the market value of Silexion Therapeutics Corp (SLXN) relative to expected sales volumes, allowing for a determination of the premium paid for future revenue growth. By analyzing the projected P/S ratio, an investor assesses the fairness of the capitalization, which for this company is supported by the stability of the oncology sector and the absence of geopolitical risks limiting access to global markets.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring Pharma)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lixte.com (LIXT)|Rasio rega marang prakiraan pendapatan citiuspharma.com|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite (CANF)|Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan